aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C

Aims Hepatocellular carcinoma (HCC) can still occur in hepatitis C virus (HCV) patients who have achieved a sustained virologic response (SVR), which remains an important clinical issue in the direct‐acting antivirals era. The current study investigated the clinical utility of the aMAP score (consis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology research 2021-09, Vol.51 (9), p.933-942
Hauptverfasser: Yamashita, Yuki, Joshita, Satoru, Sugiura, Ayumi, Yamazaki, Tomoo, Kobayashi, Hiroyuki, Wakabayashi, Shun‐ichi, Yamada, Yosuke, Shibata, Soichiro, Kunimoto, Hideo, Iwadare, Takanobu, Matsumura, Makiko, Miyabayashi, Chiharu, Okumura, Taiki, Ozawa, Sachie, Nozawa, Yuichi, Kobayashi, Natsuko, Komatsu, Michiharu, Fujimori, Naoyuki, Saito, Hiromi, Umemura, Takeji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Hepatocellular carcinoma (HCC) can still occur in hepatitis C virus (HCV) patients who have achieved a sustained virologic response (SVR), which remains an important clinical issue in the direct‐acting antivirals era. The current study investigated the clinical utility of the aMAP score (consisting of age, male, albumin–bilirubin, and platelets) for predicting HCC occurrence in HCV patients achieving an SVR by direct‐acting antivirals. Methods A total of 1113 HCV patients without HCC history, all of whom achieved an SVR, were enrolled for clinical comparisons. Results Hepatocellular carcinoma was recorded in 50 patients during a median follow‐up period of 3.7 years. The aMAP score was significantly higher in the HCC occurrence group than in the HCC‐free group (53 vs. 47, p 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13689